Facilities

Oct 23, 2017
By Pharmaceutical Technology Editors
The biotechnology company has officially opened its new Michigan research and production center for the production of spider silk-based fibers, as well as for the company’s polymer research and development program.
Oct 23, 2017
By Pharmaceutical Technology Editors
The clinical-stage biopharmaceutical company has announced the opening of a new gene therapy manufacturing facility in Modiin, Israel, which is anticipated to be the production site of the company’s lead cancer drug candidate.
Oct 23, 2017
By Pharmaceutical Technology Editors
The $72-million investment, part of a larger $850-million investment into its US operations, will allow the drugmaker to replace an outdated insulin vial-filling line and to upgrade technology at its Indianapolis manufacturing plant.
Oct 20, 2017
By Pharmaceutical Technology Editors
The company has announced that it has acquired a new bioanalysis and biomarkers services facility in Laval, Montreal, Canada to support preclinical and clinical programs.
Oct 18, 2017
By Pharmaceutical Technology Editors
The partnership and the formation of the institute intend to bring together industry, academia, and regulators to tackle challenges and provide solutions for continuous manufacturing.
Oct 18, 2017
Equipment and Processing Report
Water shortages, testing, and effluent treatment are important issues for pharma manufacturers.
Oct 16, 2017
By Pharmaceutical Technology Editors
The company announced plans to expand its viral vector process development facilities in the United States and its cleanroom facilities in the Netherlands for vector-based products.
Oct 16, 2017
By Pharmaceutical Technology Editors
The new center will serve as a regional hub where scientists and engineers can work with customers for biological development.
Oct 12, 2017
By Pharmaceutical Technology Editors
The company is investing EUR 170 million (US$201 million) to expand its vaccine manufacturing site in France for its newest influenza vaccine.
Oct 11, 2017
By Pharmaceutical Technology Editors
Johnson & Johnson’s Janssen Sciences Ireland UC will invest more than EUR 300 million (US$355 million) to expand manufacturing capacity for biologic medicines at its Ireland facility.
native1_300x100
lorem ipsum